Guaranteeing the Protection of Confidential Data in Drug Registration Files in Israel
This article was originally published in SRA
This article describes a new guideline that the Pharmaceutical Administration of Israel’s Ministry of Health has issued on the protection of data in drug registration files. The document, released in December 2008, applies to all employees of the Pharmaceutical Administration and the Institute for the Standardisation and Control of Pharmaceuticals (the institute), as well as to relevant external consultants and advisory committee members. It is particularly noteworthy because it is the first-ever issued guideline in Israel in this respect.
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.